Roflumilast + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
COPD
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Trial Timeline
Feb 1, 2012 → Feb 1, 2016
NCT ID
NCT01509677About Roflumilast + Placebo
Roflumilast + Placebo is a phase 3 stage product being developed by AstraZeneca for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT01509677. Target conditions include COPD, Chronic Obstructive Pulmonary Disease.
What happened to similar drugs?
20 of 20 similar drugs in COPD were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01509677 | Phase 3 | Completed |
| NCT01473758 | Phase 2 | Terminated |
| NCT01443845 | Approved | Completed |
| NCT01329029 | Approved | Completed |
| NCT00424268 | Phase 3 | Completed |
| NCT00313209 | Phase 3 | Completed |
| NCT00297115 | Phase 3 | Completed |
| NCT00297102 | Phase 3 | Completed |
| NCT00242320 | Phase 3 | Completed |
| NCT01365533 | Phase 2 | Completed |
Competing Products
20 competing products in COPD